---
title: "翰森製藥甲磺酸達麥利替尼片上市許可申請獲受理"
description: "翰森製藥公佈，集團自主研發的創新藥甲磺酸達麥利替尼片聯合甲磺酸阿美替尼片 (阿美樂？) 上市許可申請獲中國國家藥品監督管理局受理，用於治療表皮生長因子受體 (EGFR) 基因突變陽性經 EGFR 酪氨酸激酶抑制劑治療失敗的伴間質－上皮轉化因子擴增的局部晚期或轉移性非小細胞肺癌患者。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/277350918.md"
published_at: "2026-03-01T10:55:19.000Z"
---

# 翰森製藥甲磺酸達麥利替尼片上市許可申請獲受理

> 翰森製藥公佈，集團自主研發的創新藥甲磺酸達麥利替尼片聯合甲磺酸阿美替尼片 (阿美樂？) 上市許可申請獲中國國家藥品監督管理局受理，用於治療表皮生長因子受體 (EGFR) 基因突變陽性經 EGFR 酪氨酸激酶抑制劑治療失敗的伴間質－上皮轉化因子擴增的局部晚期或轉移性非小細胞肺癌患者。

翰森製藥 (03692.HK) 公佈，集團自主研發的創新藥甲磺酸達麥利替尼片聯合甲磺酸阿美替尼片 (阿美樂？) 上市許可申請獲中國國家藥品監督管理局受理，用於治療表皮生長因子受體 (EGFR) 基因突變陽性經 EGFR 酪氨酸激酶抑制劑治療失敗的伴間質－上皮轉化因子擴增的局部晚期或轉移性非小細胞肺癌患者。

### Related Stocks

- [159837.CN - 易方達中證生物科技主題ETF](https://longbridge.com/zh-HK/quote/159837.CN.md)
- [510660.CN - 華夏醫藥ETF](https://longbridge.com/zh-HK/quote/510660.CN.md)
- [03692.HK - 翰森制藥](https://longbridge.com/zh-HK/quote/03692.HK.md)
- [159506.CN - 富國恆生港股通創新藥及醫療保健ETF](https://longbridge.com/zh-HK/quote/159506.CN.md)
- [516930.CN - 生物科技ETF基金](https://longbridge.com/zh-HK/quote/516930.CN.md)
- [562050.CN - 華寶中證制藥ETF](https://longbridge.com/zh-HK/quote/562050.CN.md)
- [588130.CN - 華夏上證科創板生物醫藥ETF](https://longbridge.com/zh-HK/quote/588130.CN.md)
- [512010.CN - 易方達滬深300醫藥ETF](https://longbridge.com/zh-HK/quote/512010.CN.md)
- [159570.CN - 匯添富國證港股通創新藥ETF](https://longbridge.com/zh-HK/quote/159570.CN.md)
- [516500.CN - 華夏中證生物科技主題ETF](https://longbridge.com/zh-HK/quote/516500.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| China CDE Grants GenFleet’s GFH375 Breakthrough Therapy Designation for KRAS G12D NSCLC | GenFleet Therapeutics (Shanghai) Inc. has received Breakthrough Therapy Designation from China's Center for Drug Evaluat | [Link](https://longbridge.com/zh-HK/news/277376970.md) |
| Shanghai Fosun Pharmaceutical Units Trial Nod for Lung Cancer Drug in China | Shanghai Fosun Pharmaceutical Units Trial Nod for Lung Cancer Drug in China | [Link](https://longbridge.com/zh-HK/news/276886600.md) |
| Hansoh Wins EU Approval for Key Lung Cancer Drug Aumolertinib | Hansoh Wins EU Approval for Key Lung Cancer Drug Aumolertinib | [Link](https://longbridge.com/zh-HK/news/276393466.md) |
| China Medical System Gets China Acceptance for Atopic Dermatitis Drug | China Medical System Gets China Acceptance for Atopic Dermatitis Drug | [Link](https://longbridge.com/zh-HK/news/276718382.md) |
| China's Jiuyuan Genetic seeks approval for Wegovy biosimilar | Jiuyuan Genetic Biopharmaceutical has applied for approval to sell its biosimilar version of Wegovy in China, ahead of a | [Link](https://longbridge.com/zh-HK/news/276994337.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。